Proteon Therapeutics, a company founded in the Kansas City area, has begun its second phase 3 clinical trial at St. Luke’s Hospital as it works to gain FDA approval for vonapanitase, a drug designed to help kidney dialysis patients.
Proteon Therapeutics, a company founded in the Kansas City area, has begun its second phase 3 clinical trial at St. Luke’s Hospital as it works to gain FDA approval for vonapanitase, a drug designed to help kidney dialysis patients. Corbis
Proteon Therapeutics, a company founded in the Kansas City area, has begun its second phase 3 clinical trial at St. Luke’s Hospital as it works to gain FDA approval for vonapanitase, a drug designed to help kidney dialysis patients. Corbis

Testing of drug to help hemodialysis patients moves forward in Kansas City

August 12, 2015 01:30 AM